Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Convertible Debt (2022 - 2025)

ImmunityBio (IBRX) has disclosed Convertible Debt for 4 consecutive years, with $477.1 million as the latest value for Q4 2025.

  • Quarterly Convertible Debt rose 3.29% to $477.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $477.1 million through Dec 2025, up 3.29% year-over-year, with the annual reading at $477.1 million for FY2025, 3.29% up from the prior year.
  • Convertible Debt for Q4 2025 was $477.1 million at ImmunityBio, down from $500.8 million in the prior quarter.
  • The five-year high for Convertible Debt was $588.0 million in Q3 2024, with the low at $165.3 million in Q3 2023.
  • Average Convertible Debt over 4 years is $450.3 million, with a median of $488.9 million recorded in 2025.
  • Peak annual rise in Convertible Debt hit 255.73% in 2024, while the deepest fall reached 19.95% in 2024.
  • Over 4 years, Convertible Debt stood at $241.3 million in 2022, then surged by 139.13% to $577.0 million in 2023, then decreased by 19.95% to $461.9 million in 2024, then grew by 3.29% to $477.1 million in 2025.
  • According to Business Quant data, Convertible Debt over the past three periods came in at $477.1 million, $500.8 million, and $492.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.